In a wide-ranging interview with BioCentury This Week television that touched on new models for personalized medicine, proposals to create a special medical use pathway, and new drug compounding legislation, FDA Commissioner Margaret Hamburg argued the agency and industry both must adapt to the rapidly changing scientific landscape.

FDA's Nov. 19 approval of the MiSeqDx genome sequencing system from Illumina Inc. for broad clinical use exemplifies both the pace of scientific change and FDA's attempt to respond to it.